Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy

  title={Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy},
  author={Gerald Batist and Jeremy Barton and Philip Chaikin and Christine E. Swenson and Lauri Welles},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1739 - 1751}
Doxorubicin, either as a single agent or in combination regimens, is considered to be one of the most active chemotherapeutic agents in the treatment of metastatic breast cancer. However, its clinical utility is limited by a cumulative, dose-dependent cardiac myopathy that can lead to potentially fatal congestive heart failure. Considerable research has gone into improving the therapeutic index of doxorubicin-based regimens. A new liposomal formulation of doxorubicin (Myocet™, Elan… 
Liposomal Doxorubicin
Liposomal doxorubicin represents an important advance in terms of offering reduced cardiotoxicity compared with conventionalDoxorUBicin, and can be used in preference to conventional doxorbicin in a combination regimen with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
First-Line Chemotherapy with Liposomal Doxorubicin Plus Cyclofosfamide in Metastatic Breast Cancer: A Case Report of Early and Prolonged Response
The case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.
Advantages of liposomal delivery systems for anthracyclines.
Liposomes, closed vesicular structures consisting of one or more lipid bilayers, have generated a great deal of interest as drug delivery vehicles. In particular, they have been investigated for
Comparison of Two Commercially Available Pegylated Liposomal Doxorubicin Products: Doxil/Caelyx versus Lipo-Dox
The current status of newly developed polyethyleneglycol-coated liposome (PEG-liposome or pegylated lyposome) is described in this review and it’s obvious that higher plasma AUC may not always be advantageous to patients who receive pegylation liposomal doxorubicin.
Liposome Encapsulated Doxorubicin Citrate (Ledc) as an AlternativeTherapeutic Option for Patients with Recurrent Ovarian Cancer Sufferingfrom Doxorubicin-Related Cutaneous Toxicity
LEDC is a well tolerated drug and a valid therapeutic option for patients with ovarian cancer suffering from doxil-related cutaneous toxicity, according to the National Cancer Institute Common Toxicity Criteria Version 3.0.
Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects.
The purpose of this review is to draw attention to the developments of DOX-loaded nanoparticles for cancer therapy, with special a focus on enhanced intracellular uptake and reduced side-effects strategies.
Liposome-based approaches to overcome anticancer drug resistance.
Liposomes: Ideal drug delivery systems in breast cancer.
The present study aimed to review the existing issues regarding BC treatment and discuss liposome-based targeting in order to overcome barriers to conventional drug therapy.
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
The combination of Myocet® and gemcitabine at the RD is safe and has encouraging clinical activity in patients with advanced breast cancer, without apparent cardiac toxicity in anthracycline-pretreated patients.
Evaluation of Novel Doxorubicin-Loaded Magnetic Wax Nanocomposite Vehicles as Cancer Combinatorial Therapy Agents
A comprehensive in vitro validation of a combinatorial therapy nanoformulation against solid tumours is presented and the information extracted from the different in vitro models highlights the importance of advanced 3D models to fully understand the potential of this type of complex drugs.


Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison
Liposomal doxorubicin.
The results show that the toxicity of the formulation is related to drug retention in the circulation, and the antitumor activity is more sensitive to the size of the liposomes.
Liposomal anthracyclines for breast cancer.
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
The objective of this study was to compare the efficacy and toxicity of the liposome‐encapsulated doxorubicin, TLC D‐99 (Myocet, Elan Pharmaceuticals, Princeton, NJ), and conventional doxorubicin in
Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity.
P prudent medical practice mandates that physicians learn more about the mechanisms of trastuzumab-induced cardiotoxicity and develop algorithms for assessing risk/benefit ratios before extending the use of this agent to patients with less invasive forms of breast cancer.
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
  • G. Batist, G. Ramakrishnan, L. Lee
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
Anthracyclines in breast cancer: therapy and issues of toxicity
Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
There is sufficient evidence to justify consideration of epirubicin for inclusion in first-line therapies for patients with early or metastatic breast cancer, and the opportunity exists to increase dose intensity in an effort to improve efficacy.
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
Doxil (ALZA Corp., Mountain View, CA) is a formulation of doxorubicin in polyethylene‐glycol coated liposomes with a prolonged circulation time and unique toxicity profile. As yet, the effect of the
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
Caelyx is an active agent in advanced breast cancer with a safety profile that differs markedly from nonliposomal doxorubicin and the mild myelosuppression seen with this regimen would favor its use in combination chemotherapy.